Figure 3.
Compound 1 causes significant antitumor activity in KRASG12S A549 tumor xenograft model. Daily oral administration for 21 days resulted in significant and dose-dependent tumor growth inhibition.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.